0
     

Report Added
Report already added
Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 35 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ischemia Reperfusion Injury - Overview
Ischemia Reperfusion Injury - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ischemia Reperfusion Injury - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
Abfero Pharmaceuticals Inc
Amyndas Pharmaceuticals LLC
Anagenics Ltd
Apollo Therapeutics LLC
Argenx SE
Asta Pharmaceuticals Co Ltd
Axolo Pharma Inc
Balmes Transplantation SAS
Beijing Northland Biotech Co Ltd
Bolder Biotechnology Inc
Celdara Medical LLC
CFM Pharma Holding BV
Corline Biomedical AB
Curacle Co Ltd
Cypralis Ltd
Domainex Ltd
EVAS Therapeutics LLC
Faron Pharmaceuticals Oy
Gero Discovery
Gilead Sciences Inc
Glucox Biotech AB
Ischemix Inc
Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
LUCA Science Inc
Mallinckrodt Plc
Neuroene Therapeutics LLC
New Beta Innovation Ltd
New Horizons Pharma Inc
Nour Heart Therapeutics LLC
NuNerve Pty Ltd
Orion Corp
Oxitope Pharma BV
Pfizer Inc
Pharming Group NV
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Revive Therapeutics Ltd
Sairiyo Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Slate Bio Inc
Stealth BioTherapeutics Corp
TheraSource LLC
United Therapeutics Corp
Young Therapeutics LLC
Ischemia Reperfusion Injury - Drug Profiles
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANV-6L15 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-39 - Drug Profile
Product Description
Mechanism Of Action
APP-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ARGX-117 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZ-67 - Drug Profile
Product Description
Mechanism Of Action
BBT-059 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
History of Events
BT-0213 - Drug Profile
Product Description
Mechanism Of Action
BT-0301 - Drug Profile
Product Description
Mechanism Of Action
BT-0402 - Drug Profile
Product Description
Mechanism Of Action
bucillamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAB-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
CC-4066 - Drug Profile
Product Description
Mechanism Of Action
cerium oxide - Drug Profile
Product Description
Mechanism Of Action
CMX-2043 - Drug Profile
Product Description
Mechanism Of Action
History of Events
conestat alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
CU-103 - Drug Profile
Product Description
Mechanism Of Action
cyclocreatine phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
DH-404 - Drug Profile
Product Description
Mechanism Of Action
dimethyltryptamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
DMX-5804 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs for Ischemia Reperfusion Injuries - Drug Profile
Product Description
Mechanism Of Action
FAX-051T - Drug Profile
Product Description
Mechanism Of Action
Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis - Drug Profile
Product Description
Mechanism Of Action
HUB-1023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IL-233 - Drug Profile
Product Description
Mechanism Of Action
interferon beta-1a - Drug Profile
Product Description
Mechanism Of Action
History of Events
KN-93 - Drug Profile
Product Description
Mechanism Of Action
M-3mP6 - Drug Profile
Product Description
Mechanism Of Action
MG-53 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MitoDak - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies to Inhibit MMP-8 for Ischemia Reperfusion Injury and Shock - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury and Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
MP-3964 - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotide for Cardiovascular Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
ORM-10103 - Drug Profile
Product Description
Mechanism Of Action
Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-190 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Enzymes to Activate ALDH2 for Alcohol Poisoning, Ischemia Reperfusion Injury and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile
Product Description
Mechanism Of Action
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile
Product Description
Mechanism Of Action
Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
regadenoson - Drug Profile
Product Description
Mechanism Of Action
History of Events
Remodulin - Drug Profile
Product Description
Mechanism Of Action
Renaparin - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBT-272 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Ischemia Reperfusion Injury and Neuroinflammation - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Metastatic Liver Cancer and Hepatic Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CRP for Ischemic Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
SP-420 - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides for Cardiovascular Disorders, Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
tiomolibdate diammonium - Drug Profile
Product Description
Mechanism Of Action
tofacitinib citrate - Drug Profile
Product Description
Mechanism Of Action
UWA-TAT - Drug Profile
Product Description
Mechanism Of Action
Vanadis-01 - Drug Profile
Product Description
Mechanism Of Action
Vanadis-03 - Drug Profile
Product Description
Mechanism Of Action
VCP-746 - Drug Profile
Product Description
Mechanism Of Action
YQ-23 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YT-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YT-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZK-001 - Drug Profile
Product Description
Mechanism Of Action
Ischemia Reperfusion Injury - Dormant Projects
Ischemia Reperfusion Injury - Discontinued Products
Ischemia Reperfusion Injury - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: Revive Therapeutics receives FDA Orphan Drug Designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation
Jan 17, 2022: Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection, 0.4 mg/5 mL (0.08 mg/mL) single-dose pre-filled syringe
Nov 23, 2021: Revive Therapeutics files for FDA Orphan Drug Designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation
Jun 19, 2021: "Recombinant Human Thymosin ß4 for Injection" Phase IIa Clinical Trial Interim Investigator Meeting Successfully Held
Jan 20, 2020: Revive Therapeutics provides update on its cannabinoid program initiatives for drug delivery and in the prevention of ischemia and reperfusion injury from organ transplantation
May 05, 2019: Clinical trial shows promise for increasing lung transplant patients life expectancy
Aug 22, 2018: Revive Therapeutics applies to FDA For Orphan Drug Designation of Cannabidiol for treatment of Liver Transplantation
Jun 12, 2018: Corline Biomedical: Application for clinical trial of Renaparin submitted
Mar 26, 2018: UVA Launches Human Tests of Lung Transplant Drug
Aug 03, 2017: Corline Biomedical: Notice of allowance for Renaparin patent in the United States
May 04, 2017: Corline receives orphan drug status in the United States
Jan 27, 2017: Notice on the Start of Phase II Clinical Trial using 5-ALA by University of Oxford and SBI Pharmaceuticals
Dec 09, 2015: Ischemix Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound
Sep 30, 2015: Ischemix Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients
Jul 02, 2012: Pharming Announces Publication Of New Data On Ruconest’s Protective Effects After Severe Blood Loss In Journal Shock
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ischemia Reperfusion Injury - Pipeline by Abfero Pharmaceuticals Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Anagenics Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Apollo Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Argenx SE, 2022
Ischemia Reperfusion Injury - Pipeline by Asta Pharmaceuticals Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Axolo Pharma Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, 2022
Ischemia Reperfusion Injury - Pipeline by Beijing Northland Biotech Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, 2022
Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, 2022
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, 2022
Ischemia Reperfusion Injury - Pipeline by Curacle Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Cypralis Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Domainex Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by EVAS Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Faron Pharmaceuticals Oy, 2022
Ischemia Reperfusion Injury - Pipeline by Gero Discovery, 2022
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, 2022
Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Larix Bioscience LLC, 2022
Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by LUCA Science Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, 2022
Ischemia Reperfusion Injury - Pipeline by Neuroene Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by New Beta Innovation Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by New Horizons Pharma Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Nour Heart Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Pipeline by NuNerve Pty Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Orion Corp, 2022
Ischemia Reperfusion Injury - Pipeline by Oxitope Pharma BV, 2022
Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, 2022
Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Revive Therapeutics Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Sairiyo Therapeutics Inc, 2022
Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, 2022
Ischemia Reperfusion Injury - Pipeline by Slate Bio Inc, 2022
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, 2022
Ischemia Reperfusion Injury - Pipeline by TheraSource LLC, 2022
Ischemia Reperfusion Injury - Pipeline by United Therapeutics Corp, 2022
Ischemia Reperfusion Injury - Pipeline by Young Therapeutics LLC, 2022
Ischemia Reperfusion Injury - Dormant Projects, 2022
Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..1)
Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..2)
Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..3)
Ischemia Reperfusion Injury - Discontinued Products, 2022

List of Figures
Number of Products under Development for Ischemia Reperfusion Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline